Multifunctional aptamer-miRNA conjugates for targeted cancer therapy

Molecular Therapy

Volumn 22, Issue 6, 2014, Pages 1151-1163

  Esposito, Carla L ^a   Cerchia, Laura ^a   Catuogno, Silvia ^a   De Vita, Gennaro ^a   Dassie, Justin P ^b   Santamaria, Gianluca ^c   Swiderski, Piotr ^d   Condorelli, Gerolama ^a,e   Giangrande, Paloma H ^b,f   De Franciscis, Vittorio ^a  

^a CNR   (Italy)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF SALERNO   (Italy)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; MICRORNA; MICRORNA LET 7G; ONCOGENIC RECEPTOR TYROSINE KINASE AXL; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; MIRNLET7 MICRORNA, HUMAN; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXL GENE; CANCER INHIBITION; CANCER THERAPY; CELL MOTILITY; CELL SURVIVAL; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LET 7G GENE; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; ONCOGENE; RNA BINDING; RNA INTERFERENCE; TARGET CELL; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; MCF 7 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MCF-7 CELLS; MICE, NUDE; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ORGAN SPECIFICITY; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84902144911     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.5     Document Type: Article

References (50)

1. Iorio, MV and Croce, CM (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4: 143-159.
2. Garofalo, M, Condorelli, GL, Croce, CM and Condorelli, G (2010). MicroRNAs as regulators of death receptors signaling. Cell Death Differ 17: 200-208.
3. Thiel, KW and Giangrande, PH (2010). Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv 1: 849-861.
4. Ye, M, Hu, J, Peng, M, Liu, J, Liu, J, Liu, H et al. (2012). Generating Aptamers by Cell-SELEX for Applications in Molecular Medicine. Int J Mol Sci 13: 3341-3353.
5. Esposito, CL, Passaro, D, Longobardo, I, Condorelli, G, Marotta, P, Affuso, A et al. (2011). A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6: e24071.
6. Li, N, Nguyen, HH, Byrom, M and Ellington, AD (2011). Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS ONE 6: e20299.
7. Cerchia, L, Esposito, CL, Camorani, S, Rienzo, A, Stasio, L, Insabato, L et al. (2012). Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther 20: 2291-2303.
8. Liu, Z, Duan, JH, Song, YM, Ma, J, Wang, FD, Lu, X et al. (2012). Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med 10: 148.
9. Thiel, WH, Bair, T, Peek, AS, Liu, X, Dassie, J, Stockdale, KR et al. (2012). Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS ONE 7: e43836.
10. Mahlknecht, G, Maron, R, Mancini, M, Schechter, B, Sela, M and Yarden, Y (2013). Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci USA 110: 8170-8175.
11. Cerchia, L and de Franciscis, V (2010). Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 28: 517-525.
12. Zhou, J and Rossi, JJ (2011). Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21: 1-10.
13. McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015. (Pubitemid 44215395)
14. Wullner, U, Neef, I, Eller, A, Kleines, M, Tur, MK and Barth, S (2008). Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2 Curr Cancer Drug Targets 8: 554-565.
15. Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
16. Zhou, J, Swiderski, P, Li, H, Zhang, J, Neff, CP, Akkina, R et al. (2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37: 3094-3109.
17. Neff, CP, Zhou, J, Remling, L, Kuruvilla, J, Zhang, J, Li, H et al. (2011). An aptamersiRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3: 66ra6.
18. Ni, X, Zhang, Y, Ribas, J, Chowdhury, WH, Castanares, M, Zhang, Z et al. (2011). Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 121: 2383-2390.
19. Wheeler, LA, Trifonova, R, Vrbanac, V, Basar, E, McKernan, S, Xu, Z et al. (2011). Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121: 2401-2412.
20. Thiel, KW, Hernandez, LI, Dassie, JP, Thiel, WH, Liu, X, Stockdale, KR et al. (2012). Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40: 6319-6337.
21. Wilner, SE, Wengerter, B, Maier, K, de Lourdes Borba Magalhaes, M, Del Amo, DS, Pai, S et al. (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 1: e21.
22. Zhu, Q, Shibata, T, Kabashima, T and Kai, M (2012). Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur J Med Chem 56: 396-399.
23. Zhou, J, Neff, CP, Swiderski, P, Li, H, Smith, DD, Aboellail, T et al. (2013). Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 21: 192-200.
24. Zhou, J, Li, H, Li, S, Zaia, J and Rossi, JJ (2008). Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 16: 1481-1489.
25. Li, Y, Ye, X, Tan, C, Hongo, JA, Zha, J, Liu, J et al. (2009). Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28: 3442-3455.
26. Roush, S and Slack, FJ (2008). The let-7 family of microRNAs. Trends Cell Biol 18: 505-516.
27. Boyerinas, B, Park, SM, Hau, A, Murmann, AE and Peter, ME (2010). The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 17: F19-F36.
28. Esposito, CL, Catuogno, S, de Franciscis, V and Cerchia, L (2011). New insight into clinical development of nucleic acid aptamers. Discov Med 11: 487-496.
29. Wu, X, Ding, B, Gao, J, Wang, H, Fan, W, Wang, X et al. (2011). Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine 6: 1747-1756.
30. Dai, F, Zhang, Y, Zhu, X, Shan, N and Chen, Y (2012). Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target Oncol 7: 217-225.
31. Liu, N, Zhou, C, Zhao, J and Chen, Y (2012). Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest 30: 577-582.
32. Schwarz, DS, Hutvágner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208. (Pubitemid 37329583)
33. Khvorova, A, Reynolds, A and Jayasena, SD (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216. (Pubitemid 37329584)
34. Amarzguioui, M, Lundberg, P, Cantin, E, Hagstrom, J, Behlke, MA and Rossi, JJ (2006). Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc 1: 508-517.
35. Amarzguioui, M and Rossi, JJ (2008). Principles of Dicer substrate (D-siRNA) design and function. Methods Mol Biol 442: 3-10.
36. De, N, Young, L, Lau, PW, Meisner, NC, Morrissey, DV and MacRae, IJ (2013). Highly complementary target RNAs promote release of guide RNAs from human Argonaute2. Mol Cell 50: 344-355.
37. Lee, YS and Dutta, A (2007). The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025-1030. (Pubitemid 46686471)
38. Berezhnoy, A, Brenneman, R, Bajgelman, M, Seales, D and Gilboa, E (2012). Thermal Stability of siRNA Modulates Aptamer-conjugated siRNA Inhibition. Mol Ther Nucleic Acids 1: e51.
39. Goff, LA, Davila, J, Swerdel, MR, Moore, JC, Cohen, RI, Wu, H et al. (2009). Ago2 immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PLoS ONE 4: e7192.
40. Johnson, SM, Grosshans, H, Shingara, J, Byrom, M, Jarvis, R, Cheng, A et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120: 635-647. (Pubitemid 40343076)
41. Li, D, Lin, HH, McMahon, M, Ma, H and Ann, DK (1997). Oncogenic raf-1 induces the expression of non-histone chromosomal architectural protein HMGI-C via a p44/p42 mitogen-activated protein kinase-dependent pathway in salivary epithelial cells. J Biol Chem 272: 25062-25070. (Pubitemid 27415687)
42. Lupold, SE, Hicke, BJ, Lin, Y and Coffey, DS (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62: 4029-4033. (Pubitemid 34791070)
43. Shimizu, S, Takehara, T, Hikita, H, Kodama, T, Miyagi, T, Hosui, A et al. (2010). The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol 52: 698-704.
44. Schultz, J, Lorenz, P, Gross, G, Ibrahim, S and Kunz, M (2008). MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 18: 549-557. (Pubitemid 351630945)
45. Juliano, R, Alam, MR, Dixit, V and Kang, H (2008). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36: 4158-4171. (Pubitemid 351984831)
46. Qin, S, Yang, C, Wang, X, Xu, C, Li, S, Zhang, B et al. (2013). Overexpression of Smac promotes Cisplatin-induced apoptosis by activating caspase-3 and caspase-9 in lung cancer A549 cells. Cancer Biother Radiopharm 28: 177-182.
47. Zhou, J, Shum, KT, Burnett, JC and Rossi, JJ (2013). Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) 6: 85-107.
48. Cedervall, T, Lynch, I, Lindman, S, Berggard, T, Thulin, E, Nilsson, H et al. (2007). Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 104: 2050-2055. (Pubitemid 46391350)
49. Petrocca, F and Lieberman, J (2011). Promise and challenge of RNA interferencebased therapy for cancer. J Clin Oncol 29: 747-754.
50. Pastor, F, Kolonias, D, Giangrande, PH and Gilboa, E (2010). Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465: 227-230.